Siemens Healthineers Hemoglobin A1c Test for Diagnosing and Monitoring Diabetes Now Available on the Atellica Solution


TARRYTOWN, N.Y.–(BUSINESS WIRE)–Siemens Healthineers announced today the global availability of its new Atellica CH Enzymatic Hemoglobin A1c (A1c_E) Assay to assist clinicians in diagnosing and monitoring diabetes, a growing and potentially deadly disease. The International Diabetes Federation projects 642 million people worldwide will have diabetes by 2040 because of leading factors such as higher levels of urbanization, aging populations, and the growing adoption of more sedentary lifestyle

- Advertisement -